93 results about "Human kidney" patented technology

Human / human hybrid cells were made via fusion of human embryonic kidney cells (293S) and modified Burkitt's lymphoma cells (2B8). The fusion cells are useful as host cells for the recombinant expression of mammalian genes. The advantages of using these hybrid clones of human kidney- and B-cells, called HKBs, for mammalian gene expression, include (i) the cells are negative for immunoglobulin expression, (ii) the cells grow easily in plasma protein-free medium (with or without the addition of recombinant insulin) as suspension cultures in a shake flask or in a fermenter (iii) the cells are very susceptible for transfection of DNA, and (iv) the cells secrete high levels of heterologous recombinant proteins, such as recombinant monoclonal antibodies, soluble ICAM-1, rIL-4, and rFVIII.

An implantable human kidney replacement unit. Fully functional self contained, providing patients with end stage renal disease the freedom of traveling and moving about normally. Replacing donor kidneys. Implanted in the flank with at least one inlet and outlet tube each, sutured to the iliac artery and vain, at least one urine tube to the ureter. The housing constructed of anti-coagulant bacteriostatic materials has a plurality of reverse-osmosis process chambers with semipemeable membranes through the unit, followed by osmosis-diffusion chambers and membranes. Blood from the artery enters the first of the chambers. Small molecules such as water, magnesium, sodium, potassium, calcium, urea etc. are extracted from the blood according to their weight in atomic mass units as blood wipes past the self-cleaning membrane cartridges in the chambers. Molecules are further separated and urea sent to the bladder with excess water and electrolytes. The remainder is channeled to at least one diffusion chamber and reabsorbed into the blood. The same process is repeated in the other chambers where selected larger molecules such as creatinine and phosphorus are excreted, and some diffused back into the blood.

The present disclosure provides human renal stem cells. Also described are human renal stem cells isolated from the papillary region of the human kidney and methods of isolating the same. Also described are methods for culturing, characterizing, and differentiating the same, including methods for identifying human renal stem cells that are positive for Nestin and CD133, and methods for allowing the cells to differentiate into neurons.

In one aspect, the present invention relates to a mammalian cell-based high-throughput assay for the profiling and screening of human epithelial sodium channel (hENaC) cloned from a human kidney c-DNA library and is also expressed in other tissues including human taste tissue. The present invention further relates to amphibian oocyte-based medium-throughput electrophysiological assays for identifying human ENaC modulators, preferably ENaC enhancers. Compounds that modulate ENaC function in a cell-based ENaC assay are expected to affect salty taste in humans. The assays described herein have advantages over existing cellular expression systems. In the case of mammalian cells, such assays can be run in standard 96 or 384 well culture plates in high-throughput mode with enhanced assay results being achieved by the use of a compound that inhibits ENaC function, preferably an amiloride derivative such as Phenamil. In the case of the inventive oocyte electrophysiological assays (two-electrode voltage-clamp technique), these assays facilitate the identification of compounds which specifically modulate human ENaC. The assays of the invention provide a robust screen useful to detect compounds that facilitate (enhance) or inhibit hENaC function. Compounds that enhance or block human ENaC channel activity should thereby modulate salty taste in humans.

The invention belongs to the field of drugs, and relates to an antineoplastic drug, particularly an indazole / azaindazole-based diarylcarbamide / thiocarbamide-structure antineoplastic drug. The structural general formulae of the indazole / azaindazole-based diarylcarbamide / thiocarbamide-structure antineoplastic drug are disclosed as Formula (Ia) and (Ib), wherein Z is an N or C atom; W is an atom or group, such as O, S, NH, NOH, NCH or the like; M is O, S, N, CH or the like; n is 1 or 2; and Y and R are respectively halogen atom, H, R1, CF3, OCF3, OH, OR2, OCOR3, NH2, NHR4, NR52, NHCOR6, carboxy group, ester group, cyano-group, sulfhydryl group, alkylthio group, sulfuryl group, sulfoxide group, sulfo-group, sulfonate group, sulfamide group, ketone group, aldehyde group, nitro-group or nitroso-group. The pharmacological experiment proves that the drug has favorable antineoplastic effect on human lung cancer, human kidney cancer, human colon cancer, human liver cancer, human stomach cancer and human breast cancer.

The invention relates to 2-aryl-1,3-isoquinoline diketone anti-tumor compound and a synthesis method and application thereof. The 2-aryl-1,3-isoquinoline diketone anti-tumor compound has the chemical structural formula I and the chemical structural formula II, wherein R represents the hydrogen, the hydroxy or the methoxyl, and Ar is phenyl, one or more of the halogen-atom substituted phenyl, the trifluoromethylphenyl, the 3-acetylenyl phenyl, the 6-benzothiazolyl, the 2-acetylamino pyridine and the like. The 2-aryl-1,3-isoquinoline diketone anti-tumor compound has a novel structure, and the synthesis method of the 2-aryl-1,3-isoquinoline diketone anti-tumor compound is easy to implement. The antiproliferative activity assay shows that most compounds have significant functions of inhibiting the growth of human prostate cancer cells PC3 and human kidney cancer cells 786-0, and the in vivo anti-S180 tumor activity test shows that the activity of the compound 21 is significantly stronger than that of Gefitinib.

Kidney disease is diagnosed by measuring urinary catalytic iron in humans. Progressive kidney disease is treated by administering an iron chelator to humans. In particular, the progression of kidney disease essentially can be halted and the severity of kidney disease can be reduced by the administration of iron chelators to humans afflicted with a progressive kidney disease. The methods include measuring catalytic iron content in urine in a human afflicted with a progressive kidney disease and administering an iron chelator to the human. The method can include measuring total urinary protein content, blood urea nitrogen or creatinine in a blood sample before, during or after the administration of an iron chelator.

[Problem] To provide a preservative solution for cells, tissues and organs using a rare sugar and a preservation method using the solution.[Means for Resolution] A preservative solution for cryopreservation of animal or human organs and animal or plant tissues or cells, the solution containing a rare sugar D-allose. A preservative solution for cryopreservation of the human kidney, cells derived from animals or humans, or human or animal sperm and / or ovum and / or fermented ovum in which the cryopreservation is conducted at from −5 to 20° C. A preservative solution for cryopreservation of cells derived from animals or humans, or human or animal sperm and / or ovum and / or fermented ovum in which the cryopreservation is conducted at a temperature at which to start freezing to −196° C. A method for cryopreservation of an animal or human organ and an animal or plant tissue or cell at a low temperature, which comprises (a) refluxing or immersing a preservative solution for cryopreservation containing a rare sugar D-allose and the organ or the tissue or mixing the cell therewith, and (b) cooling the organ, the tissue or the cell to a low temperature of from −5 to 20° C.

Method for examining kidney disease, which comprises detecting fatty acid binding protein derived from kidney tissues, which is present in specimen collected from mammal excluding Rodents. By the present method, it is possible to obtain test results, which may be very important information for diagnosis or prognosis of kidney disease that has been very difficult in the past. Based on test results obtained by the present method, it may be possible to select a suitable method for treatment of kidney disease with taking into consideration risks such as the prognosis, etc. Besides, the present method can be applied to, in addition to the kidney disease samples, urine samples as well, so that the examination procedure can be simple and efficient.

The present disclosure provides human renal stem cells. Also described are human renal stem cells isolated from the papillary region of the human kidney and methods of isolating the same. Also described are methods for culturing, characterizing, and differentiating the same, including methods for identifying human renal stem cells that are positive for Nestin and CD133, and methods for allowing the cells to differentiate into neurons.

The present invention relates to reagents and methods for the diagnosis, prognosis and treatment of cancer. Specifically, the present invention relates to the use of proteins encoding transmembrane superfamily member 6 (TM4SF6), synaptophysin-like protein (SYPL), stomatin-like 2 (STOML2), Ras-associated GTP-binding protein (RAGA), nucleotide-sensitive Chloride channel 1A (CLNS1A), prion protein (p27-30) (PRNP), guanine nucleotide-binding protein β2-like 1 (GNB2L1), guanine nucleotide-binding protein 4 (GNG4), integral membrane protein 2B (ITM2B), integral membrane protein 1 (ITM1), transmembrane 9 superfamily member 2 (TM9SF2), opiate receptor-like 1 protein (OPRL1), low-density lipoprotein receptor-related protein 4 (LRP4), human kidney Nucleic acid and amino acid sequences of glomerular epithelin 1 (GLEPP1), toll-like receptor 3 (TLR3), and / or zona pellucida glycoprotein 3A (ZP3) for early and advanced non-steroid-specific cancer diagnosis, cancer prognosis, and For screening therapeutic agents that modulate the gene expression and / or biological activity of the protein. The invention further relates to biotechniques designed to inhibit gene expression and / or biological activity of said proteins, including the use of agents identified in the screening assays described herein, vector delivery of antisense polynucleotide sequences, and the Antibody targeting the protein. In specific embodiments, the protein is of human origin.

The invention discloses a cordyceps sinensis oyster peptide compound with the function of tonifying the kidney and producing sperms. The cordyceps sinensis oyster peptide compound is prepared from, byweight, 25-50 parts of cordyceps sinensis polysaccharide compounds, 30-45 parts of oyster peptide, 12-18 parts of rhizoma polygonati, 4-8 parts of fructus lycii and the balance medical or food healthcare auxiliaries. By being compatible with raw materials of oyster peptide and the like, better play is given to the medicine effect of the cordyceps sinensis polysaccharide compounds; meanwhile, through the specific characteristicof the cordyceps sinensis polysaccharide compounds, the efficacies of rhizoma polygonati, oyster peptide and fructus lycii are further improved; the cordyceps sinensispolysaccharide compounds are compatible with oyster peptide and fructus lycii to achieve the functions of boosting qi and nourishing yin, tonifying the kidney and producing the sperms, and in practice, the effects of effectively tonifying the kidney, producing the sperms and improving the human kidney function are achieved.

The invention relates to an isolated multipotent glomerular mesenchymal stem cell derived from adult human kidney (hGL-MSC), which is characterised by the marker profile CD133−, CD146+, CD34− and CD105+. A method of preparing the hGL-MSC of the invention form decapsulated glomeruli is also disclosed, as well as the uses of the hGL-MSC of the invention in the regenerative treatment of the kidney, particularly for the treatment of injuries or diseases affecting renal glomeruli.

The invention discloses a recombinant adenovirus expression vector based on human rare serotype adenovirus HAd49 and a construction method of the recombinant adenovirus expression vector. According tothe invention, a genome of wild adenovirus HAd49 is used as a basis, through a direct cloning method by genome, an E1 coding region and an E3 coding region are deleted, an I-CeuI enzyme cutting siteand a PI-SceI enzyme cutting site are inserted into an E1 deletion region, meanwhile, the E4orf6 of the human adenovirus Ad5 is used for replacing the E4orf6 of the HAd49, so that the success rate ofpackaging the recombinant virus in a human kidney embryo cell (HEK293) and the titer of the packaged recombinant virus are improved, and the recombinant adenovirus expression vector Ad49 with replication defects is obtained. The expression vector can be used for expressing various antigens, and provides a basis for research and development of vaccines and biological medicines.

The invention discloses a construction method of a human nerve stem cell bank. The method comprises the following steps: carrying out human urine separation to obtain human kidney epithelial cells, subculturing the human kidney epithelial cells, partially cryopreserving the human kidney epithelial cells, inducing the subcultured human kidney epithelial cells to form nerve stem cells, separating the nerve stem cells obtained after induction, carrying out amplification culturing, identifying the nerve stem cells, cryopreserving the confirmed nerve stem cells, coding and warehousing. The method avoids the use of fetal bovine serum in the whole process, eliminates the introduction of foreign proteins, and reduces hidden troubles; the method allows the successfully induced stem cells with activity to be preserved in order to form the bank, and the stem cells can be provided for clinic use within 3d; and a cryopreservation mode in the method is characterized in that nerve bulbs with a certain size are cryopreserved, a protection agent is introduced step by step in the cryopreservation process, and the cooling rate is set in grading, so recovered nerve stem cells still have high cell viability and activity, and have significantly higher than cell viability and activity than the recovered nerve stem cells preserved through current routine slow low-temperature cryopreservation methods.

The invention relates to synthesis of dihydropyrazol sulfonamide derivatives containing benzodioxane skeletons. The synthesis is characterized by being provided with a general formula shown in descriptions. The dihydropyrazol sulfonamide derivatives containing the benzodioxane skeletons play an obvious role in inhibiting human mammary cancer cells (MCF-7), cervical carcinoma cells (HeLa), lung cancer cells (A549), liver cancer cells (HepG2) and matrix metalloproteinase-2 (MMP-2), and meanwhile, show cell toxicity, which is equivalent to or better than that of positive control drugs, to human kidney epithelial cells (293T). Thus, the dihydropyrazol sulfonamide derivatives containing the benzodioxane skeletons can be applied to the preparation of anti-tumor drugs. The invention discloses a preparation method and anti-tumor bioactivity of the dihydropyrazol sulfonamide derivatives containing the benzodioxane skeletons.

The method is to determine Klotho (KL) protein in human blood via KL protein antibody. The preparation of KL protein antibody includes: amplifying partial cDNA sequence of KL gene from human kidney tissue by RT-PCR technology; cloning the segment cDNA to pET plamid to constitute KL protein segment expressing vector; coverting E.coli cell strain BL21 / DE3 with the expressing vector and IPTE induction to make the converted bacteria to express exogenous protein; collecting and crushing the cultured and induced cell, Ni-NTA combination and separation to obtain purified KL protein segment; injecting the purified KL protein segment to rabbit, collecting rabbit serum and purifying with saturated ammonium sulfate to obtain KL protein antibody. The method of the present invention may be used clinically.

The invention relates to a method for preparing fine dioscin and an application of the fine dioscin to antitumor aspect. The preparation method comprises the following steps of: weighing medicinal materials, putting into an extracting tank, soaking the medicinal materials with a water-containing organic solvent of which the amount is 3-12 times (v / w) that of the medicinal materials for 30-100 minutes, heating to 40-100 DEG C, refluxing or extracting with other auxiliary methods for 1-8 hours, draining an extracting solution, and extracting for 2-5 times; concentrating and recovering the solvent, draining a residual liquid, standing, precipitating a precipitate out, filtering, and drying and smashing a filter cake to obtain a crude product; and repeatedly crystalizing the crude product with the solvent to obtain a pure product of which the purity is over 95 percent. As proved by results of in-vitro and in-vivo antitumor tests on the fine dioscin, the fine dioscin prepared with the method has an antitumor effect, and particularly has better effects on the aspect of inhibition of human intestinal cancers, human kidney cancers, human prostatic cancers and human mammary cancer tumor cells. The fine dioscin prepared with the method can be prepared into antitumor tablets, capsules, injections, oral liquids and the like.

The invention discloses a normal-temperature perfusion system, in particular discloses a normal-temperature perfusion system for storing human kidneys, and belongs to the technical field of designing and manufacturing medical instruments. The invention provides a normal-temperature perfusion system for storing human organs, which can obviously reduce functional lesions to a stored kidney during storage of transplanted organs. The normal-temperature perfusion system comprises a perfusion pump, a human organ storage device and a perfusion liquid monitoring component, wherein a perfusion liquid input end and a perfusion liquid output end of the perfusion pump are penetrated into the human organ storage device and then are communicated with a perfusion body fluid output end and a perfusion body fluid output end of a human organ needed to be stored respectively; the perfusion liquid monitoring component is connected with the perfusion liquid output end of the perfusion pump in series; the human organ storage device also comprises a temperature adjusting mechanism; and the ambient temperature of the human organ storage device is adjusted and controlled by the temperature adjusting mechanism.

The invention discloses a recombinant adenovirus expression vector, which is characterized in that an E1 coding region and an E3 coding region are deleted through a molecular cloning method based on agenome of a wild-type adenovirus SAd23, I-Ceu I and PI-Sce I cleavage sites are inserted in the E1 deletion region, and meanwhile, an E4 coding region of SAd23 is replaced with the E4 coding region of an adenovirus human serotype Ad5, so that the success rate of packaging the recombinant virus and the titer of the recombinant virus in human kidney embryo cells (HEK293) are improved, and the replication-defective recombinant adenovirus expression vector is obtained. The vector has the advantages that: 1. a large fragment of plasmids are constructed through a direct molecular cloning method, the method is simple and easy to operate, and can be used for constructing any large fragment of the vector; 2. the adenovirus expression vector can be constructed through multiple cloning connections,the steps are simple; and 3. screening positive clones at the bacterial level is easier and faster, and the construction time of the adenovirus vector is shortened.

The invention discloses a method for constructing a zebrafish kidney progenitor cell marker transgenic line. The method comprises the following steps: a gene knock-in method is used to construct a transgenic fish line of Six2a:GFF in a zebrafish, wherein the fish line hybridizes with UAS:GFP, UAS:Dendra2-NTR to specifically label kidney progenitor cells in the kidney or delete kidney progenitor cells, as well as overexpression and inhibition of the genes are carried out in kidney progenitor cells. The line can be used for high-throughput drug screening to provide the method to create kidney progenitors in human kidneys.

We have disclosed an induced pluripotent stem cell and the method of preparing the induced pluripotent stem cell from a human kidney-derived cell. More particularly, we have disclosed a human kidney-derived iPS cell which may be differentiated into cells of ectoderm, mesoderm, and endoderm lineages.

The invention relates to the field of gene medical treatment, and particularly relates to circSPECC1 for treating human kidney cancer and application thereof. The invention relates to application of the circSPECC1 for treating human kidney cancer in preparing a medicine for treating human kidney cancer. The beneficial effects are as follows: based on the gene of human kidney cancer OS-RC-2 cell YB-1, the circSPECC1 interacts with miR-615 to target and regulate the expression of HIP1 (Huntington Interaction Protein 1) and Caspase 9 gene, plays an important role in invasion and proliferation ofhuman kidney cancer, and can effectively inhibit the proliferation and invasion ability of human kidney cancer OS-RC-2 cells by inhibiting circSPECC1. The implementation of the project has important significance for filling the gap of human kidney cancer biotherapy and perfecting the current human kidney cancer comprehensive treatment measures, and also has far-reaching significance for preventingand treating tumors of other tissues and organs.

An implantable human kidney replacement unit. Fully functional self contained, providing patients with end stage renal disease the freedom of traveling and moving about normally. Replacing donor kidneys. Implanted in the flank with at least one inlet and outlet tube each, sutured to the iliac artery and vain, at least one urine tube to the ureter. The housing constructed of anti-coagulant bacteriostatic materials has a plurality of reverse-osmosis process chambers with semipemeable membranes through the unit, followed by osmosis-diffusion chambers and membranes. Blood from the artery enters the first of the chambers. Small molecules such as water, magnesium, sodium, potassium, calcium, urea etc. are extracted from the blood according to their weight in atomic mass units as blood wipes past the self-cleaning membrane cartridges in the chambers. Molecules are further separated and urea sent to the bladder with excess water and electrolytes. The remainder is channeled to at least one diffusion chamber and reabsorbed into the blood. The same process is repeated in the other chambers where selected larger molecules such as creatinine and phosphorus are excreted, and some diffused back into the blood.

The invention provides a kidney surgery model capable of simulating blood circulating and urine generating functions. Compared with existing kidney simulation devices which are appearance models onlyand have the problems of being simple in structure, unitary in function, low in simulation degree and unsupportive of teaching demonstration and surgery operation, the kidney surgery model can be usedfor preclinical teaching and scientific research. The model simulating human kidney organs and parts thereof is made according to a proportion of 1:1, thereby being high in simulation level, and a relation between kidney blood circulation and urine generation can be simulated through a pulse pump, a pressure control part and a valve; parts of the model are assembled and spliced, so that the modelcan be used for clinical surgical operation and teaching demonstration, medical staff can simulate related process operations of a kidney transplanting surgery, and understanding on kidney organ andsurgical success rate of the medical staff are improved.

A novel cell suited for mass production of Hemagglutinating Virus of Japan (HVJ), a method for obtaining the cell and use of the cell are disclosed. The human cell is originated from a transformed human kidney cell line, the doubling time thereof in logarithmic growth phase in suspension culture in a serum-free medium is not more than 40 hours, the cell has a freeze-recovery property, the maximum density of viable cells in suspension culture is not less than 106 cells / mL, and HVJ can grow in the cell. The method for obtaining the human cell comprises the steps of suspension-culturing a human transformed kidney cell line in a serum-free medium, and cloning the grown cells; and selecting, from the cloned cells, a cell whose doubling time in logarithmic growth phase in suspension culture in a serum-free medium is not more than 40 hours, which has a freeze-recovery property, whose maximum density of viable cells in suspension culture is not less than 106 cells / mL, in which HVJ can grow.

The invention discloses a 22-nor-stigmasta thiosemicarbazone compound and a preparing method and application thereof. The structural formula of the 22-nor-stigmasta thiosemicarbazone compound is shown in the description. In vitro cancer cell growth and proliferation activity inhibition tests show that the prepared 22-nor-stigmasta thiosemicarbazone compound has a remarkable inhibition effect on various tumor cell strains such as human nipple thyroid gland cancer cells, human oral cavity epidermoid carcinoma cells and cervical cancer. Meanwhile, the 22-nor-stigmasta thiosemicarbazone compound is free of cytotoxicity on human kidney epithelial cells (HEK293T) and can be used for preparing medicine for treating cancer.

The invention provides synthesis for a 4-(3-(3-(4-clocoumarol)-acylhydrazone)-5-phenyl-pyrazol) benzene sulfonamide derivate. The synthesis is characterized by being implemented according to the general formula (please see the formula in specification). The 4-(3-(3-(4-clocoumarol)-acylhydrazone)-5-phenyl-pyrazol) benzene sulfonamide derivate has the obvious inhibiting effect on culture of cervical cancer cells (Hela), human melanoma cells (F10) and hepatoma carcinoma cells (HepG2) and has cytotoxicity equivalent to or better than that of positive control drugs for human kidney epithelial cells (293T). Accordingly, the 4-(3-(3-(4-clocoumarol)-acylhydrazone)-5-phenyl-pyrazol) benzene sulfonamide derivate can be used for preparing anti-tumor drugs. The invention discloses a preparing method of the benzene sulfonamide derivate and anti-tumor biological activity.

The invention provides a substituted benzofuran derivative. A chemical structure of the derivative is as shown in general formula I. The invention further provides a preparation method of the formulaI, the preparation method is as shown in the following reaction formula described in the specification, wherein R and R' are defined the same as the specification. In-vitro proliferation inhibition experiment researches of human tumor cells show that the substituted benzofuran derivative has excellent inhibition effects on tumor cells such as human hepatoma cells HLF, human intestinal cancer cellsHCT116, human breast cancer cells MDA-MB-231, human prostate cancer cells DU145, human melanoma cells A375, human colon cancer cells Lovo, human kidney cancer cells 786-o, human chronic myeloid leukemia cells K562, human gastric cancer cells MGC-803, human pancreatic cancer cells PANC-1, can be used for preparing an anti-tumor drug, has low acute toxicity and good water solubility, and has good clinical application prospects. The preparation method provided by the invention is suitable for industrial production.